Photo of Paolo Tarantino taken from Twitter
Feb 1, 2024, 17:31
Paolo Tarantino: Any agnostic approval should not stop efforts in biomarker discovery for ADCs
Paolo Tarantino, Medical Oncologist, Research Fellow at Dana-Farber Cancer Institute, shared a post on X/Twitter:
“Of note, any agnostic approval should not stop efforts in biomarker discovery for ADCs. T-DXd works well for HER2 expressing (≥1+) breast cancer, but overexpression/amplification is required for GI tumors and mutations are the best predictors for NSCLC. Complexity is the norm, in oncology.
T-DXd granted Priority Review in the US for patients with metastatic HER2-positive (IHC 3+) solid tumors. One step closer to the first agnostic ADC, as well as the first agnostic HER2-targeted treatment.”
Read further.
Source: Paolo Tarantino/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 22, 2024, 05:59
Dec 22, 2024, 05:31